TerminatedPHASE1, PHASE2NCT04033159
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
Studying Centronuclear myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dynacure
- Principal Investigator
- Chris Freitag, MDDynacure
- Intervention
- DYN101(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2020 – 2022
Study locations (8)
- Antwerp University Hospital (UZA), Edegem, Belgium
- Rigshospitalet, Copenhagen Neuromuscular Center, Neurocentret, Copenhagen, Denmark
- Institut de Myologie, Paris, France
- universitätsklinikum Essen, Kinderklinik I, Sozialpädiatrisches Zentrum, Essen, Germany
- Friedrich Baur Institut - Neurologische Klinik LMV, Klinikum Innenstadt, München, Germany
- Radboud University Medical Centre, Nijmegen, Netherlands
- MRC centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, United Kingdom
- Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04033159 on ClinicalTrials.govOther trials for Centronuclear myopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07021820Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear MyopathyUniversity of Erlangen-Nürnberg Medical School
- RECRUITINGNCT06157268The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.Radboud University Medical Center
- RECRUITINGNCT04064307Myotubular and Centronuclear Myopathy Patient RegistryNewcastle-upon-Tyne Hospitals NHS Trust
- RECRUITINGNCT00272883Molecular and Genetic Studies of Congenital MyopathiesBoston Children's Hospital